Chemotherapy of Malaria.
Rept. no. 11 (Annual) 1 Jun 76-30 Sep 77,
MIAMI UNIV FLA LEO RANE RESEARCH LAB
Pagination or Media Count:
The investigations undertaken during this report period included two primary and one secondary drug screening program in malaria, along with a primary and secondary drug screening program in African trypanosomiasis. The malarial system used Plasmodium berghei infected mice while the African trypanosomiasis system used Trypanosoma rhodesiense infected mice. The first primary drug screen in malaria assessed compounds for blood schizonticidal activity. 7,114 compounds were tested, with 1,124 exhibiting blood schizonticidal activity. The second primary screen in malaria assessed compounds for prophylactic antimalarial activity against sporozoite induced infections. 831 compounds were tested for prophylactic antimalarial activity and 405 had curative effects while 149 were more active than primaquine. The primary test in African trypanosomiasis included evaluating compounds for trypanosomicidal activity against a drug-sensitive line of parasites. 4,235 compounds were tested for trypanosomicidal activity and 396 were found to be active. The secondary test with African trypanosomiasis involved developing three major drug-resistant lines a suramin-resistant, a stilbamidine-resistant, and a berenil-resistant line.